CLINICAL ROLE -
Advancing LBCL Treatment Through MRD Monitoring and Allogeneic CAR T-Cell Therapy
A phase 2 trial investigates MRD detection and therapy advancements.
Read More
ASHP Midyear: Expert Discusses GLP-1 Medications and Incretin Mimetics for Diabetes Care
Jennifer Clements, a clinical professor and the director of pharmacy education at the University of South Carolina, discusses the pharmacists role in diabetes care.
From Abemaciclib to Trastuzumab Deruxtecan: Highlights From the 2024 San Antonio Breast Cancer Symposium
Experts presented results that may transform treatment and clinical practice strategies.
From Blinatumomab to Venetoclax: Highlights From the 66th American Society of Hematology Annual Meeting and Exposition
Presentations detail clinical trial results and drugs in the pipeline.
Key Insights From ASH and SABCS Showcase Advancements for the Field of Oncology Pharmacy
ASHP Midyear: Expert Discusses the GLP-1 Landscape for Diabetes Care
Pharmacy Times interviews Jennifer Clements, a clinical professor and the director of pharmacy education at the University of South Carolina, about glucagon-like peptide-1 receptors for diabetes treatment.
ASHP Midyear: New Therapies Are on the Horizon for Steatotic Liver Disease, but Access Challenges Remain
New medications like glucagon-like peptide-1 agonists and resmetirom show promise in reversing fatty liver disease and preventing progression.
Watch
ASHP Midyear: Pharmacists Play Key Role in Managing Chronic Kidney Disease With Emerging Therapies
Pharmacists can educate patients on controlling risk factors and stay up-to-date on emerging therapies like SGLT2 inhibitors and finerenone that can slow disease progression.
ASHP Midyear: Elevated Lp(a) Levels Pose Significant Cardiovascular Risk, Experts Emphasize Need for Awareness
Lp(a) is a critical risk factor for atherosclerotic cardiovascular disease, but current lipid-lowering therapies are largely ineffective at lowering Lp(a) levels.
ASHP Midyear: Bolus Dose of Antibiotic May Improve in Septic Shock
Administering first-dose antibiotics to septic shock patients via IV push rather than continuous infusion could improve the speed of antibiotic delivery and reduce logistical challenges.
ASH 2024: Zanubrutinib Monotherapy, With Obinutuzimab Demonstrates Durable Efficacy and Safety in CLL/SLL
Constantine Tam, MD, discusses zanubrutinib's efficacy in CLL/SLL, emphasizing its durability, high response rates, safety considerations, and evolving therapeutic potential in combination with other agents.
ASHP Midyear: Pharmacists Can Advocate for Expanded RSV Vaccination Recommendations
Pharmacists are crucial in educating patients, identifying eligible individuals, and promoting uptake of the newly expanded RSV vaccination recommendations for older adults.
ASH 2024: Cilta-Cel Achieves Sustained MRD Negativity in Patients With Multiple Myeloma
Yi Lin, MD, PhD, highlights the importance of achieving MRD negativity in multiple myeloma, CAR T-cell therapy outcomes, and the critical role of pharmacists in patient care.
ASHP Midyear: Biosimilars Offer Cost Savings, But Barriers to Adoption Remain
Adoption barriers include insurance coverage, patient and provider education, and regulatory hurdles that require aligned initiatives across stakeholders.
ASHP Midyear: Pharmacists Play Key Role in Comprehensive COPD Management, Emphasizing Cost Considerations
Pharmacists can significantly improve chronic obstructive pulmonary disease (COPD) management by promoting non-pharmacological interventions.
ASHP Midyear: Appropriate Use of High-Cost IVIG Therapy for BK Nephropathy Needs Further Studying
Pharmacists are encouraged to work closely with health care providers to ensure appropriate use of high-cost Intravenous immunoglobulin (IVIG) therapy for BK nephropathy.
Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting
Pharmacy Times attended the 2024 San Antonio Breast Cancer Symposium from December 10 to December 13.
Listen
ASHP Midyear: 2025 GOLD Report Updates Highlight Cardiovascular Risks, New Therapies for COPD Patients
The 2025 GOLD Report emphasizes the importance of tailoring combination treatments based on patient factors like eosinophil counts and exacerbation history.
ASHP Midyear: Optimizing IVIG Therapy for BK Nephropathy in Kidney Transplant Patients Can Improve Outcomes
Pharmacists can optimize IVIG treatment for BK nephropathy in kidney transplant recipients by educating providers and monitoring for infusion reactions.
ASHP Midyear: Vaccination Among Older Adults Prevents Severe RSV Infections
Pharmacists are essential in preventing the significant health and economic burden of respiratory syncytial virus (RSV) infections in older adults through vaccination.
ASHP Midyear: New Oral Treatment, Antibody Drug Conjugates Offer Additional Options for Breast Cancer
Pharmacists identify appropriate patients for new oral and antibody drug conjugate treatments and provide counseling to help patients navigate the evolving treatment landscape.
ASHP Midyear: Compounding Medications Provide Personalized Options for Patients
Compounding pharmacies play a vital role in meeting the unique needs of patients, but pharmacists must adhere to strict safety standards and regulations.
ASHP Midyear: Real-World Data Collection Helps to Facilitate Successful Biosimilar Adoption
The evolving regulatory policies around biosimilar interchangeability is crucial for driving successful biosimilar adoption in the marketplace.
ASHP Midyear: Automated Compounding Workflows and Comprehensive Record-Keeping Reduce Errors
Pharmacy errors can happen due to manual processes, but they can be mitigated through adoption of automated IV workflow technology and comprehensive compounding records.
ASHP Midyear: Expert Highlights Standardization, Technology to Enhance Compounding Safety and Quality
Standardizing observational competencies and utilizing technology to improve compounding accuracy can ensure safety and quality of compounded medications.
Research Shows Efgartigimod Costs Are Far Higher Than Therapeutic Plasma Exchange for Myasthenia Gravis
Higher costs of efgartigimod alfa are primarily driven by its status as a newly approved, brand-name therapy without a generic alternative.
ASHP Midyear: Food Insecurity Impacted Hypertension for Patients, Especially in Rural Areas
Food insecurity in rural communities can affect hypertension, but pharmacists can mitigate the impact by educating themselves on nutrition options for low-income individuals.
ASH 2024: Nuvisertib Demonstrates Durable Response in Relapsed/Refractory Myelofibrosis
Firas El Chaer, MD, discusses newly-presented data at ASH demonstrating nuvisertib's effectiveness in myelofibrosis.
ASHP Midyear: Pharmacist Emphasizes Individualized Approach to Antiplatelet Therapy Management
Snehal Bhatt discusess the need to individualize antiplatelet therapy decisions based on a comprehensive assessment of each patient's unique risk factors for thrombosis and bleeding.
SABCS 2024: The Persistent Association Between Obesity and Breast Cancer Outcomes
Obesity is associated with increased distant recurrence and breast cancer mortality in all types of early-stage breast cancer.